In another study (phase II, single-cohort, 25-center, global study; NCT02435849) of CD19 targeted CAR T cells in pediatric and young adult patients with refractory or relapsed B cell acute lymphoblastic leukemia (B-ALL), overall remission rate of 81% was reported at three months after infusion. This evidence concerns the gene CD19 and B-cell acute lymphoblastic leukemia.